Menu Search
Equities

Genomed SA

GEN:WSE

Genomed SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)28.00
  • Today's Change0.00 / 0.00%
  • Shares traded123.00
  • 1 Year change-22.65%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Genomed SA grew revenues 9.88% from 20.46m to 22.48m while net income improved 174.07% from 337.96k to 926.25k.
Gross margin44.00%
Net profit margin2.66%
Operating margin4.13%
Return on assets5.77%
Return on equity6.56%
Return on investment6.39%
More ▼

Cash flow in PLNView more

In 2023, Genomed SA increased its cash reserves by 50.81%, or 1.77m. The company earned 1.97m from its operations for a Cash Flow Margin of 8.75%. In addition the company generated 9.53k cash from financing while 203.90k was spent on investing.
Cash flow per share0.9039
Price/Cash flow per share30.98
Book value per share7.02
Tangible book value per share6.95
More ▼

Balance sheet in PLNView more

Genomed SA has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 5.26m.
Current ratio6.63
Quick ratio4.64
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in PLN

Year on year, growth in earnings per share excluding extraordinary items increased 174.07%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years)-8.94
EPS (TTM) vs
TTM 1 year ago		113.47
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.